Proteome Sciences PLC
LSE:PRM

Watchlist Manager
Proteome Sciences PLC Logo
Proteome Sciences PLC
LSE:PRM
Watchlist
Price: 1.49 GBX 7.97% Market Closed
Market Cap: £5.2m

P/OCF

-113.6
Current
1 188%
More Expensive
vs 3-y average of -8.8

Price to Operating Cash Flow (P/OCF) ratio compares a company`s market value to the cash it generates from its core operations.

P/OCF
-113.6
=
Market Cap
GBX4.5m
/
Operating Cash Flow
£-46k

Price to Operating Cash Flow (P/OCF) ratio compares a company`s market value to the cash it generates from its core operations.

P/OCF
-113.6
=
Market Cap
GBX4.5m
/
Operating Cash Flow
£-46k

Valuation Scenarios

Proteome Sciences PLC is trading above its 5-year average

If P/OCF returns to its 5-Year Average (6.4), the stock would be worth GBX-0.08 (106% downside from current price).

Statistics
Positive Scenarios
0/3
Maximum Downside
-106%
Maximum Upside
No Upside Scenarios
Average Downside
102%
Scenario P/OCF Value Implied Price Upside/Downside
Current Multiple -113.6 GBX1.49
0%
5-Year Average 6.4 GBX-0.08
-106%
Industry Average 0.4 GBX-0
-100%
Country Average 0.1 GBX-0
-100%

Forward P/OCF
Today’s price vs future operating cash flow

Not enough data available to calculate forward P/OCF

Peer Comparison

All Multiples
P/OCF
P/E
All Countries
Close
Market Cap P/OCF P/E
UK
Proteome Sciences PLC
LSE:PRM
5.2m GBP -113.6 -1.7
US
PerkinElmer Inc
LSE:0KHE
962.6B USD 1 651.2 3 990.7
US
Thermo Fisher Scientific Inc
NYSE:TMO
173.9B USD 21 25.4
US
Danaher Corp
NYSE:DHR
127.8B USD 19.9 34.7
KR
Samsung Biologics Co Ltd
KRX:207940
82.3T KRW 36.6 46.1
CN
WuXi AppTec Co Ltd
SSE:603259
298.6B CNY 17.2 15.5
CH
Lonza Group AG
SIX:LONN
32.9B CHF 29.2 -122.9
US
Agilent Technologies Inc
NYSE:A
32.7B USD 23.4 25.3
US
Waters Corp
NYSE:WAT
29.4B USD 45.1 45.8
US
IQVIA Holdings Inc
NYSE:IQV
27.8B USD 10.5 20.5
US
Mettler-Toledo International Inc
NYSE:MTD
26B USD 27.2 29.9
P/E Multiple
Earnings Growth PEG
UK
Proteome Sciences PLC
LSE:PRM
Average P/E: 470.4
Negative Multiple: -1.7
N/A N/A
US
P
PerkinElmer Inc
LSE:0KHE
3 990.7
46%
86.8
US
Thermo Fisher Scientific Inc
NYSE:TMO
25.4
18%
1.4
US
Danaher Corp
NYSE:DHR
34.7
26%
1.3
KR
Samsung Biologics Co Ltd
KRX:207940
46.1
15%
3.1
CN
WuXi AppTec Co Ltd
SSE:603259
15.5
6%
2.6
CH
Lonza Group AG
SIX:LONN
Negative Multiple: -122.9 N/A N/A
US
Agilent Technologies Inc
NYSE:A
25.3
18%
1.4
US
Waters Corp
NYSE:WAT
45.8
41%
1.1
US
IQVIA Holdings Inc
NYSE:IQV
20.5
25%
0.8
US
Mettler-Toledo International Inc
NYSE:MTD
29.9
10%
3

Market Distribution

Lower than 100% of companies in United Kingdom
Percentile
0th
Based on 2 384 companies
0th percentile
-113.6
Low
0 — 0.1
Typical Range
0.1 — 0.2
High
0.2 —
Distribution Statistics
United Kingdom
Min 0
30th Percentile 0.1
Median 0.1
70th Percentile 0.2
Max 2 143.8

Proteome Sciences PLC
Glance View

Proteome Sciences Plc engages in the applied proteomics and peptidomics services and applications. The company is headquartered in Addlestone, Surrey and currently employs 27 full-time employees. The firm is engaged in biomarker research and development in applied proteomics and workflows using its techniques to detect and characterize differentially expressed proteins in diseases for diagnostic, prognostic and therapeutic applications. The company operates through the EU (the United Kingdom and Germany) and the United States geographic regions. Through the United Kingdom segment, it provides protein separation and MS capabilities for identification and analysis of post-translational modification of proteins in protein phosphorylation, image analysis and bioinformatics. Through the Germany segment, it provides protein profiling technologies, such as Tandem Mass Tags (TMT), which offers quantitation of proteins for the discovery of biomarkers. The company has research agreements with various institutions in the United States.

PRM Intrinsic Value
3.07 GBX
Undervaluation 51%
Intrinsic Value
Price GBX1.49
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett